
Kringle Pharma,Inc. — Investor Relations & Filings
Kringle Pharma, Inc. is a late clinical-stage biopharmaceutical company focused on the research and development of regenerative medicines for intractable and rare diseases. The company's core technology is based on recombinant human Hepatocyte Growth Factor (HGF), an endogenous protein with tissue-protective, regenerative, and repairing functions. Kringle Pharma has established a platform to manufacture pharmaceutical-grade HGF protein and is conducting clinical trials for several indications. Key development programs target conditions including acute spinal cord injury, vocal fold scarring, and Amyotrophic Lateral Sclerosis (ALS).
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 第三者割当により発行された第16回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ | 2026-05-20 | Japanese | |
| 2026年9月期 第2四半期決算説明会 質疑応答について | 2026-05-18 | Japanese | |
| 2026年9月期 第2四半期決算説明会資料 | 2026-05-14 | Japanese | |
| 確認書 | 2026-05-11 | Japanese | |
| 半期報告書-第25期(2025/10/01-2026/09/30) | 2026-05-11 | Japanese | |
| 2026年9月期第2四半期決算短信〔日本基準〕(非連結) | 2026-05-11 | Japanese |
Browse filings by year
7 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
7 filings
| |||||
| 46571324 | 第三者割当により発行された第16回新株予約権(行使価額修正条項付)の大量行使に関するお知らせ | 2026-05-20 | Japanese | ||
| 46541032 | 2026年9月期 第2四半期決算説明会 質疑応答について | 2026-05-18 | Japanese | ||
| 46884590 | 2026年9月期 第2四半期決算説明会資料 | 2026-05-14 | Japanese | ||
| 44906051 | 確認書 | 2026-05-11 | Japanese | ||
| 44906024 | 半期報告書-第25期(2025/10/01-2026/09/30) | 2026-05-11 | Japanese | ||
| 46882740 | 2026年9月期第2四半期決算短信〔日本基準〕(非連結) | 2026-05-11 | Japanese | ||
| 46877181 | 米国子会社への増資に関するお知らせ | 2026-04-15 | Japanese | ||
|
2025
5 filings
| |||||
| 10377418 | 確認書 | 2025-12-19 | Japanese | ||
| 10377412 | 有価証券報告書-第24期(2024/10/01-2025/09/30) | 2025-12-19 | Japanese | ||
| 7239554 | 有価証券届出書(組込方式) | 2025-07-16 | Japanese | ||
| 7264669 | 確認書 | 2025-05-12 | Japanese | ||
| 7264672 | 半期報告書-第24期(2024/10/01-2025/09/30) | 2025-05-12 | Japanese | ||
|
2024
3 filings
| |||||
| 7290851 | 臨時報告書 | 2024-12-23 | Japanese | ||
| 7290847 | 確認書 | 2024-12-23 | Japanese | ||
| 7290853 | 有価証券報告書-第23期(2023/10/01-2024/09/30) | 2024-12-23 | Japanese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
Kringle Pharma,Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/14352/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=14352 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=14352 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=14352 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 14352}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Kringle Pharma,Inc. (id: 14352)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.